Syndax Pharmaceuticals (SNDX) Raw Materials (2025 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Raw Materials of $30.7 million for Q1 2026, up 1661.04% year-over-year from $1.7 million in Q1 2025, and up 5.75% quarter-over-quarter from $29.0 million in Q4 2025.
Powered by 
Analysis
Syndax Pharmaceuticals (SNDX) Raw Materials (2025 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Raw Materials history runs 2 years deep, the most recent figure standing at $30.7 million for Q1 2026.
- In Q1 2026, Raw Materials rose 1661.04% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $30.7 million (up 1661.04% YoY), while the FY2025 annual figure was $29.0 million, changed N/A from the prior year.
- Raw Materials for Q1 2026 stood at $30.7 million, up from $29.0 million in the prior quarter.
- The five-year high for Raw Materials was $30.7 million in Q1 2026, with the low at $1.7 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.28 Bn | 60.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.20 Mn |
| Mar 31, 2026 | 30.70 Mn |
| Dec 31, 2025 | 29.03 Mn |
| Sep 30, 2025 | 21.40 Mn |
| Jun 30, 2025 | 14.18 Mn |
| Mar 31, 2025 | 1.74 Mn |